Τόμος 29 (2011) – Τεύχος 3 – Άρθρο 4 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 29 (2011) – Issue 3 – Article 4 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Νικόλαος Κακαλέτσης¹, Αγγελική Γιαννούλη², Μαρία Μυρωνίδου-Τζουβελέκη³

¹Ιατρός, Μεταπτυχιακός Φοιτητής Προγράμματος Μεταπτυχιακών Σπουδών, Ιατρική Σχολή. Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάς
²Ειδικευόμενη Ιατρός Παθολογικής Ανατομικής, Αντικαρκινικό Νοσοκομείο Θεσσαλονίκης Θεαγένειο, Θεσσαλονίκη, Ελλάς
³Αναισθησιολόγος, Καθηγήτρια Φαρμακολογίας, Α’ Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή, Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάς

Nikolaos Kakaletsis¹, Aggeliki Giannouli², Maria Myronidou-Tzouveleki¹

¹A’ Laboratory of Pharmacology, Medical School, Aristotle University, Thessaloniki, Greece
²Laboratory of Pathology, Theagenion Anticancer Hospital, Thessaloniki, Greece

2. International Diabetes Federation: IDF Diabetes Atlas [article online]. 4th ed, Brussels, Belgium: International Diabetes Federation; (2009). Available at: www. diabetesatlas.org. Accessed May 1, 2011

3. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007 [article online]. Atlanta, GA: Centers for Disease Control and Prevention, 2008
Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. Accessed May 1, 2011

4. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A., Pollak M., Regensteiner J.G., Yee D.: Diabetes and Cancer: A Consensus Report. CA Cancer J. Clin, 60: 207-221 (2010)

5. Straughan J.L.: Focus on metformin – a major cardio-vascular medication, ‘diabesity – the biggest epidemic in human history’. Cardiovasc. J. Afr. 18: 331-333 (2007)

6. Gottlieb B., Auld W.H.R.: Metformin in treatment of diabetes mellitus. BMJ 10: 681-682 (1962)

7. Καραμήτσος Δ.Θ.: Διαβητολογία. Κεφάλαιο 6, Θεραπεία του Σακχαρώδη Διαβήτη, σελ. 242-248. Εκδόσεις Σιώκης, Αθήνα, 2009

8. Εθνικός Οργανισμός Φαρμάκων. Εθνικό Συνταγολόγιο 2007, σελ. 367-368. Εκδόσεις ΕΟΦ, Αθήνα, 2007

9. Greenhalgh T.: How to read a paper: the basics of evidence-based medicine. 4th ed, Chapter 2, Searching the literature, pp. 15-30, Wiley-Blackwell Publishing, West Sussex, 2010

10. Moher D., Liberati A., Tetzlaff J., Altman D.G.: The Prisma Group. Methods of systematic reviews and meta-analysis: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. J. Clin. Epidemiol. 62: 1006-1012 (2009)

11. McFarland M.S., Cripps R.: Diabetes mellitus and increased risk of cancer: Focus on metformin and the insulin analogs. Pharmacotherapy 30: 1159-1178 (2010)

12. Gonzalez-Angulo A.M., Meric-Bernstam F.: Metformin: A therapeutic opportunity in breast cancer. Clin. Cancer Res. 16: 1695-1700 (2010)

13. Papanas N., Maltezos E., Mikhailidis D.P.: Metformin and cancer: Licence to heal? Expert. Opin. Invest. Drugs 19: 913-917 (2010)

14. Sahra I.B., Marchand-Brustel Y.L., Tanti J., Bost F.: Metformin in cancer therapy: A new perspective for an old antidiabetic drug? Mol. Cancer Ther. 9: 1092-1099 (2010)

15. Jalving M., Gietema J.A., Lefrandt J.D., Jong S.D., Reyners A.K.L., Gans R.O.B., et al.: Metformin: Taking away the candy for cancer? Eur. J. Cancer 46: 2369-2380 (2010)

16. Cufí S., Vazquez-Martin A., Oliveras-Ferraros C., Martin-Castillo B., Joven J., Menendez J.A.: Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): From cancer stem cells to aging-associated fibrosis. Cell Cycle 9: 4461-4468 (2010)

17. Wysocki P.J., Wierusz-Wysocka B.: Obesity, hyperin-sulinemia and breast cancer: Novel targets and a novel role for metformin. Expert. Rev. Mol. Diagn. 10: 509-519 (2010)

18. Vázquez-Martín A., Oliveras-Ferraros C., del Barco S., Martín-Castillo B., Menéndez J.A.: mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). Clin. Transl. Oncol. 11: 455-459 (2009)

19. Martin-Castillo B., Vazquez-Martin A. Oliveras-Ferraros C., Menendez J.A.: Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 9: 1057-1064 (2010)

20. Yang X., So W.Y., Ma R.C.W., Kong A.P.S., Man H.L., Yu L., et al.: Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: The Hong Kong diabetes registry. Diabetes Care 34: 375-380 (2011)

21. Lee M., Hsu C., Wahlqvist M.L., Tsai H., Chang Y., Huang Y.: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: A representative population prospective cohort study of 800,000 individuals. BMC Cancer 11: (2011)

22. Bosco J.L.F., Antonsen S., Sorensen H.T., Pedersen L., Lash T.L.: Metformin and incident breast cancer among diabetic women: A population-based case-control study in Denmark. Cancer Epidemiol. Biomarkers Prev. 20: 101-111 (2011)

23. Colquhoun A., Venier N., Vandersluis A., Fleshner N., Pollak M., Klotz L., et al.: Utilizing metformin to enhance the efficacy of androgen deprivation therapy in the treatment of prostate cancer. J. Urol. 185: 293 (2011)

24. Rattan R., Giri S., Hartmann L.C., Shridhar V.: Met-formin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J. Cell. Mol. Med. 15: 166-178 (2011)

25. Oliveras-Ferraros C., Cufi S., Vazquez-Martin A., Torres-Garcia V.Z., Barco S.D., Martin-Castillo B., et al.: Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the antidiabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGF(beta)-induced oncomiR miRNA-181a. Cell Cycle 10: 1144-1151 (2011)

26. Vazquez-Martin A., Oliveras-Ferraros C., Cufí S., Del Barco S., Martin-Castillo B., Lopez-Bonet E., et al.: The antidiabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. Oncol. Rep. 25: 135-140 (2011)

27. Yasmeen A., Beauchamp M., Piura E., Segal E., Pollak M., Gotlieb W.H.: Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins. Gynecol. Oncol. 121: 492-498 (2011)

28. Monami M., Colombi C., Balzi D., Dicembrini I., Giannini S., Melani C., et al.: Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 34: 129-131 (2011)

29. Biernacka K.M., Holly J.M.P., Uzoh C., Gillatt D., Persad R., Perks C.M.: Metformin counter-acts hyper-glycaemia induced chemoresistance of prostate cancer cells. Eur. Urol. 10 (Suppl.): 293-294 (2011)

30. Colquhoun A., Venier N., Vandersluis A., Fleshner N., Pollak M., Klotz L., et al.: Utilizing metformin as a radio-sensitizing agent in the treatment of prostate cancer. J. Urol. 185: 296 (2011)

31. Goodwin P.J., Stambolic V., Lemieux J., Chen B.E., Parulekar W.R., Gelmon K.A., et al.: Evaluation of metformin in early breast cancer: A modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res. Treat. 126: 215-220 (2011)

32. Dowling R.J.O., Goodwin P.J., Stambolic V.: Under-standing the benefit of metformin use in cancer treatment. BMC Medicine 9: 33 (2011)

33. Kourelis T.V., Siegel R.D.: Metformin and cancer: new applications for an old drug. Med. Oncol.: [Article in Press], (2011)

34. Azoulay L., Dell’Aniello S., Gagnon B., Pollak M., Suissa S.: Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol. Bio-markers Prev. 20: 337-344 (2011)

35. Janjetovic K., Vucicevic L., Misirkic M., Vilimanovich U., Tovilovic G., Zogovic N., et al.: Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur. J. Pharmacol. 651: 41-50 (2011)
36. Berstein L.M., Boyarkina M.P., Teslenko S.Y.: Familial diabetes is associated with reduced risk of cancer in diabetic patients: a possible role for metformin. Med. Oncol. [Article in Press], (2011)